Abingworth Clinical Co-Development Fund 'Open For Business'
This article was originally published in Scrip
International investment group Abingworth has closed its eleventh life sciences fund, raising $105m for its Abingworth Clinical Co-Development Fund (ACCF) which will offer a novel co-development investment approach in the life science space.
You may also be interested in...
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.